Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer
Top Cited Papers
- 10 July 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (20), 2366-2371
- https://doi.org/10.1200/jco.2015.65.4327
Abstract
Older adults are at increased risk for chemotherapy toxicity, and standard oncology assessment measures cannot identify those at risk. A predictive model for chemotherapy toxicity was developed (N = 500) that consisted of geriatric assessment questions and other clinical variables. This study aims to externally validate this model in an independent cohort (N = 250). Patients age ≥ 65 years with a solid tumor, fluent in English, and who were scheduled to receive a new chemotherapy regimen were recruited from eight institutions. Risk of chemotherapy toxicity was calculated (low, medium, or high risk) on the basis of the prediction model before the start of chemotherapy. Chemotherapy-related toxicity was captured (grade 3 [hospitalization indicated], grade 4 [life threatening], and grade 5 [treatment-related death]). Validation of the prediction model was performed by calculating the area under the receiver-operating characteristic curve. The study sample (N = 250) had a mean age of 73 years (range, 65 to 94 [standard deviation, 5.8]). More than one half of patients (58%) experienced grade ≥ 3 toxicity. Risk of toxicity increased with increasing risk score (36.7% low, 62.4% medium, 70.2% high risk; P < .001). The area under the curve of the receiver-operating characteristic curve was 0.65 (95% CI, 0.58 to 0.71), which was not statistically different from the development cohort (0.72; 95% CI, 0.68 to 0.77; P = .09). There was no association between Karnofsky Performance Status and chemotherapy toxicity (P = .25). This study externally validated a chemotherapy toxicity predictive model for older adults with cancer. This predictive model should be considered when discussing the risks and benefits of chemotherapy with older adults.This publication has 28 references indexed in Scilit:
- Biological, Clinical, and Psychosocial Correlates at the Interface of Cancer and Aging ResearchJNCI Journal of the National Cancer Institute, 2012
- Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter StudyJournal of Clinical Oncology, 2011
- Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401Journal of Clinical Oncology, 2011
- Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled TrialsJournal of General Internal Medicine, 2011
- Role of Age and Health in Treatment Recommendations for Older Adults With Breast Cancer: The Perspective of Oncologists and Primary Care ProvidersJournal of Clinical Oncology, 2008
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trialsCancer, 2002
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsThe New England Journal of Medicine, 1999
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960